Provided by Tiger Trade Technology Pte. Ltd.

AptarGroup

121.99
-2.7000-2.17%
Post-market: 121.990.00000.00%17:51 EDT
Volume:381.35K
Turnover:46.74M
Market Cap:7.85B
PE:20.71
High:124.21
Open:123.94
Low:121.76
Close:124.69
52wk High:164.28
52wk Low:103.23
Shares:64.38M
Float Shares:64.38M
Volume Ratio:0.61
T/O Rate:0.59%
Dividend:1.83
Dividend Rate:1.50%
EPS(TTM):5.89
EPS(LYR):5.89
ROE:15.10%
ROA:6.66%
PB:2.94
PE(LYR):20.71

Loading ...

ATR Plane Missing Near Makassar with 10 on Board

Tempo
·
Jan 17

Avation Secures 12-Year ATR 72-600 Lease with Cambodian Airways

TIPRANKS
·
Jan 16

AptarGroup Inc. Highlights Pharma Leadership and Innovation in Drug Delivery Solutions

Reuters
·
Jan 15

AptarGroup Partners with CastleVax for Phase II Intranasal COVID-19 Vaccine Trial

Reuters
·
Jan 14

AptarGroup Partners with Bausch and Lomb on Beat the Blink Eye Care Technology

Reuters
·
Jan 13

A Look At AptarGroup (ATR) Valuation After Ave Maria Growth Fund Highlights Undervaluation And Industry Leadership

Simply Wall St.
·
Jan 11

Is AptarGroup (ATR) Quietly Reframing Its Pharma Story Around Data‑Driven Health Platforms?

Simply Wall St.
·
Jan 09

Press Release: Aptar Announces 2026 Quarterly Conference Call Dates

Dow Jones
·
Jan 08

AptarGroup Inc. published an update to their financial calendar

Reuters
·
Jan 08

AptarGroup Partners with ŌURA to Integrate Migraine Buddy with Oura Ring

Reuters
·
Jan 07

AptarGroup Shares Fall After Wells Fargo Downgrade

MT Newswires Live
·
Jan 07

AptarGroup Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
Jan 06

Wells Fargo Downgrades AptarGroup to Equalweight From Overweight, Price Target is $133

MT Newswires Live
·
Jan 06

AptarGroup to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Aceh Tamiang Approves Land for 500 Flood Victims' Homes

Tempo
·
Dec 30, 2025

Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development

Reuters
·
Dec 22, 2025

Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment

Dow Jones
·
Dec 18, 2025

AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment

Reuters
·
Dec 18, 2025

AptarGroup Chief Accounting Officer Daniel Ackerman Reports Disposal of Common Shares

Reuters
·
Dec 16, 2025

Did AptarGroup’s (ATR) Legal and Inventory Strains Just Challenge Its Innovation-Led Premium Narrative?

Simply Wall St.
·
Dec 11, 2025